- Zacks Small Cap Research•12 days ago
The company expects grant revenue to begin to increase in the fourth quarter of 2016 and continue to increase into 2017. Total revenue decreased to $535,334 in the third quarter 2016 from $580,334 for the third quarter of 2015. Adjusted net loss per common share was $(0.02) for the quarters ended September 30, 2016, compared to net loss per share of (0.03) for third quarter of 2015.
- Marketwired•12 days ago
SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article covering Pressure BioSciences Inc.'s recently announced financial ...
- Accesswire•12 days agoWallStreet Research Announces Availability of Updated Corporate Profile Coverage On Pressure BioSciences, Inc. (OTCQB: PBIO)
NEW YORK, NY / ACCESSWIRE / November 21, 2016 / WallStreet Research™ (WSR), a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated ...
PBIO : Summary for PRESSURE BIOSCIENC COM USD0.01 - Yahoo Finance
Pressure BioSciences, Inc. (PBIO)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.28 - 0.32|
|52 Week Range||0.26 - 0.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.77|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|